Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
[Preprint]. 2024 Jun 17:rs.3.rs-4463390.
doi: 10.21203/rs.3.rs-4463390/v1.

Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness

Affiliations

Breast organoid suspension cultures maintain long-term estrogen receptor expression and responsiveness

Joan Brugge et al. Res Sq. .

Update in

Abstract

Organoid cultures offer a powerful technology to investigate many different aspects of development, physiology, and pathology of diverse tissues. Unlike standard tissue culture of primary breast epithelial cells, breast organoids preserve the epithelial lineages and architecture of the normal tissue. However, existing organoid culture methods are tedious, difficult to scale, and do not robustly retain estrogen receptor (ER) expression and responsiveness in long-term culture. Here, we describe a modified culture method to generate and maintain organoids as suspension cultures in reconstituted basement membrane (Matrigel). This method improves organoid growth and uniformity compared to the conventional Matrigel dome embedding method, while maintaining the fidelity of the three major epithelial lineages. Using this adopted method, we are able to culture and passage purified hormone sensing (HS) cells that retain ER responsiveness upon estrogen stimulation in long-term culture. This culture system presents a valuable platform to study the events involved in initiation and evolution of ER-positive breast cancer.

PubMed Disclaimer

Conflict of interest statement

Competing interests JSB is a scientific advisory board (SAB) member of Frontier Medicines and eFFECTOR Therapeutics. JEG is a paid consultant for Helix and an uncompensated consultant for Konica Minolta and Earli. DD receives research funding from Canon, Inc (not related to work in this manuscript).

Figures

Figure 1
Figure 1
a) Established breast organoid cultures derived using the conventional Matrigel dome method (passage 5–6, ref. 14) were dissociated and either re-cultured in Matrigel domes or as suspension cultures in 5% Matrigel for more than two months. b) Representative brightfield images of six matched organoid lines grown as Matrigel domes (MD) or suspension cultures (SC) and their corresponding percentage of HS, LASP and BA cells based on FACS sorting using EpCAM and CD49f antibodies (4x magnification, scale bar 200 μm). c) Mean organoid size of the indicated matched cultures grown as domes or in suspension. A total of 30 organoids per line per culture condition was measured using Image J. ** P value <0.01, *** P value <0.001, **** P value <0.0001, t-Test.
Figure 2
Figure 2
a) Minced normal breast tissues from two reductive mammoplasty samples were dissociated and used to derive matched Matrigel dome and suspension organoid cultures. Scheme was created with BioRender.com b) Representative brightfield images of the two matched organoid lines grown as Matrigel domes (MD) or suspension cultures (SC) for 5 passages and their corresponding mean organoid size. Scale bar 200 μm. A total of 30 organoids per line per culture condition were measured using Image J. ***P value <0.001, **** P value <0.0001, t-Test. c) Percentage of EdU-positive cells in the two organoid lines at passage 5. d) Percentage of HS, LASP and BA cells based on EpCAM/CD49f expression. e) Percentage of EdU-positive cells in the indicated organoid lines 10 days after changing the culture condition from suspension to Matrigel domes (SC -> MD) or reseeding as suspension culture (SC -> SC).
Figure 3
Figure 3
a) Organoid cultures were dissociated into single cells, FACS sorted into HS, LASP and BA cells based on differential expression of EpCAM/CD49f and total RNA was extracted for bulk RNA sequencing. b) Principal Component Analysis (PCA) plot showing the HS, LASP and BA cell clusters isolated from organoids in Matrigel domes and suspension cultures. c-e) Heatmaps showing the breast epithelial subtype-specific gene expression (ref. 15) across the samples.
Figure 4
Figure 4
a) Representative brightfield images of four suspension cultures derived from single sorted HS cells based on expression of EpCAM/CD49f and cultured more than 2 weeks. 4x magnification, scale bar 200 μm. b) Representative flow cytometry plot of HS cultures isolated from ORG6. c) Percentage of HS, LASP and BA cells based on EpCAM/CD49f expression of HS cultures isolated from ORG4 (n=4) and ORG6 (n=3) and cultured for over 2 months, mean±SD. d) Percentage of HS cells based on expression EpCAM/CD49f in HS cultures isolated from 8 different organoid lines and cultured for more than 2 months. e) Representative immunofluorescence confocal images of HS cultures isolated from ORG2. Conjugated antibodies targeting FOXA1, CD133 and α-SMA were used to detect the three different epithelial lineages and DAPI for nuclei staining. 20x magnification, scale bar 100 μm.
Figure 5
Figure 5
a) Expression of the indicated ER target genes in triplicate cultures from ORG2 and ORG5 suspension cultures after estrogen treatment for seven days, assessed by qRT-PCR (n=3, mean±SD). *P value <0.05, ** P value < 0.01, *** P value <0.001, **** P value <0.0001, t-Test. b) Heatmap showing early and late estrogen response gene expression (ref. 30) in HS cells isolated from 3 organoid lines in suspension cultures then treated with or without estrogen for seven days (duplicate) with P-value <0.05 as the cutoff. c) Expression of the indicated ER target genes in triplicate HS cultures isolated from 3 organoid lines and treated with or without estrogen for seven days (n=3, mean±SD), assessed by qRT-PCR. *P value <0.05, ** P value < 0.01, t-Test. d) Representative immunofluorescence confocal images of HS cultures from ORG1 and ORG2 treated with or without estrogen (E2) and stained for Estrogen receptor (ER) and Progesterone receptor (PR), scale bar 100 μm.

References

    1. Guillen K. P. et al. A human breast cancer-derived xenograft and organoid platform for drug discovery and precision oncology. Nat Cancer 3, 232–250 (2022). - PMC - PubMed
    1. Lukasiewicz S. et al. Breast Cancer-Epidemiology, Risk Factors, Classification, Prognostic Markers, and Current Treatment Strategies-An Updated Review. Cancers (Basel) 13 (2021). - PMC - PubMed
    1. Sorlie T. et al. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A 98, 10869–10874 (2001). - PMC - PubMed
    1. Waks A. G. & Winer E. P. Breast Cancer Treatment: A Review. JAMA 321, 288–300 (2019). - PubMed
    1. Lumachi F., Brunello A., Maruzzo M., Basso U. & Basso S. M. Treatment of estrogen receptorpositive breast cancer. Curr Med Chem 20, 596–604 (2013). - PubMed

Publication types

LinkOut - more resources